MAP2K7 and prostate carcinoma: Previous studies reported that PLK1 promotes cell growth and epithelial–mesenchymal transition through the CRAF-MEK-ERK pathway in various cancers, including gastric cancer [28], breast cancer [29], and prostate cancer [15].